


# PRODUCT INFORMATION



## PF-06700841 (tosylate)

Item No. 26125

**CAS Registry No.:** 2140301-96-6  
**Formal Name:** [(1S)-2,2-difluorocyclopropyl]  
[3-[2-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-methanone,  
4-methylbenzenesulfonate  
**MF:** C<sub>18</sub>H<sub>21</sub>F<sub>2</sub>N<sub>7</sub>O • C<sub>7</sub>H<sub>8</sub>O<sub>3</sub>S  
**FW:** 561.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 224 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

PF-06700841 (tosylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the PF-06700841 (tosylate) in the solvent of choice, which should be purged with an inert gas. PF-06700841 (tosylate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of PF-06700841 (tosylate) in these solvents is approximately 10 mg/ml. PF-06700841 (tosylate) is also slightly soluble in ethanol.

PF-06700841 (tosylate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PF-06700841 (tosylate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PF-06700841 (tosylate) has a solubility of approximately 0.05 mg/ml in a 1:20 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

PF-06700841 is an inhibitor of JAK1 and tyrosine kinase 2 (TYK2; IC<sub>50</sub>s = 17 and 23 nM, respectively).<sup>1</sup> It is selective for JAK1 and TYK2 over JAK2 and JAK3 (IC<sub>50</sub>s = 77 and 6,494 nM, respectively). PF-06700841 selectively inhibits IFN-α/STAT3 signaling over erythropoietin/STAT5 signaling in human whole blood (IC<sub>50</sub>s = 30 and 577 nM, respectively). It reduces increases in hind paw volume in a rat model of adjuvant-induced arthritis in a dose-dependent manner.

### Reference

1. Fensome, A., Ambler, C.M., Arnold, E., *et al.* Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). *J. Med. Chem.* (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM